Management of ductal pancreatic cancer: The oncologists view: systemic treatment options in 2018

2Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The majority of patients diagnosed with pancreatic cancer have inoperable disease at the time of presentation. For this reason, systemic treatment is the cornerstone of therapy and more options for systemic therapy have now become available than were a decade ago. Methods: In this short review, we will give an overview on the systemic therapeutic landscape in 2018 and briefly discuss the challenging topic of neoadjuvant therapy. Results: However, there are a lot of unsolved questions and an urgent need of more clinical trials and new therapies. Conclusions: In conclusion, despite recent advances, there remains much room for improvement in all aspects of treatment for pancreatic cancer.

Cite

CITATION STYLE

APA

Djanani, A., Schmiderer, A., Niederreiter, L., Niederreiter, M., & Tilg, H. (2019, June 1). Management of ductal pancreatic cancer: The oncologists view: systemic treatment options in 2018. European Surgery - Acta Chirurgica Austriaca. Springer-Verlag Wien. https://doi.org/10.1007/s10353-019-0583-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free